Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hypertension

Endothelin-receptor antagonists for treating hypertension

Nature Reviews Nephrology volume 6, pages 192–194 (2010)Cite this article

Subjects

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some uncertainty.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Weber, M. A. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374, 1423–1431 (2009).

    Article  CAS  Google Scholar 

  2. Saito, Y., Nakao, K., Mukoyama, M. & Imura, H. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322, 205 (1990).

    CAS  PubMed  Google Scholar 

  3. Smolander, J. et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin. Pharmacol. Ther. 85, 628–634 (2009).

    Article  CAS  Google Scholar 

  4. Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403–1419 (2008).

    Article  CAS  Google Scholar 

  5. Gaddam, K. K. et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 168, 1159–1164 (2008).

    Article  CAS  Google Scholar 

  6. Gonzaga, C. C. & Calhoun, D. A. Resistant hypertension and hyperaldosteronism. Curr. Hypertens. Rep. 10, 496–503 (2008).

    Article  CAS  Google Scholar 

  7. Wenzel, R. R. et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J. Am. Soc. Nephrol. 20, 655–664 (2009).

    Article  Google Scholar 

  8. Weir, M. R. & Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. (in press).

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, 21201, MD, USA

    Matthew R. Weir

Authors
  1. Matthew R. Weir
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weir, M. Endothelin-receptor antagonists for treating hypertension. Nat Rev Nephrol 6, 192–194 (2010). https://doi.org/10.1038/nrneph.2010.14

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.14

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing